{
    "organizations": [],
    "uuid": "6a05da44cc5c4812263f2b88f0be908ade08704a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mirati-therapeutics-announces-prog/brief-mirati-therapeutics-announces-progress-of-lead-programs-idUSASC09X56",
    "ord_in_thread": 0,
    "title": "BRIEF-Mirati Therapeutics Announces Progress Of Lead Programs",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " Mirati Therapeutics Inc:\n* MIRATI THERAPEUTICS ANNOUNCES PROGRESS OF LEAD PROGRAMS AND PROVIDES UPDATED POSITIVE CLINICAL TRIAL RESULTS FOR IMMUNO-ONCOLOGY COMBINATION TRIALS\n* MIRATI THERAPEUTICS INC - MRTX849 ON TRACK FOR AN INVESTIGATIONAL NEW DRUG SUBMISSION IN Q4 OF 2018\n* MIRATI THERAPEUTICS - SITRAVATINIB BEING EVALUATED IN PHASE 2 STUDY IN COMBINATION WITH NIVOLUMAB HAS BEEN WELL-TOLERATED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T04:43:00.000+03:00",
    "crawled": "2018-04-25T14:51:05.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "mirati",
        "therapeutic",
        "inc",
        "mirati",
        "therapeutic",
        "announces",
        "progress",
        "lead",
        "program",
        "provides",
        "updated",
        "positive",
        "clinical",
        "trial",
        "result",
        "combination",
        "trial",
        "mirati",
        "therapeutic",
        "inc",
        "mrtx849",
        "track",
        "investigational",
        "new",
        "drug",
        "submission",
        "q4",
        "mirati",
        "therapeutic",
        "sitravatinib",
        "evaluated",
        "phase",
        "study",
        "combination",
        "nivolumab",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}